Nunes RAB, Avezum A, de Oliveira Marques M, Baiocchi OCCG, et al. Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis. Ann Hematol 2024 Aug 17. doi: 10.1007/s00277-024-05921.
PMID: 39153144